Business
Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019
Conference Call Scheduled for 8:30am ET / 3:30pm IST BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today
About this update from Entera Bio Ltd.
[{"type":"text","content":"Conference Call Scheduled for 8:30am ET / 3:30pm IST\nBOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S. financial markets open on Thursday, November 21, 2019. \n The Company will host a conference call at 8:30 am Eastern Time to discuss the results and provide a corporate update. A live audio webcast of the presentation will be available via the “Investor Relations” page of the Entera Bio website, www.enterabio.com, or by clicking here. A replay of the webcast will be archived on Entera website for approximately 45 days following the call. Conference call details are as follows: Thursday, November 21, 2019 @ 8:30 am Eastern Time From the US:1 855 547-3865International: 1 409 217-8523From Israel: 1 809 315 362Conference ID: 3677455Webcast: https://edge.media-server.com/mmc/p/i5yx6yjw About Entera Bio Ltd. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis. Entera has developed a proprietary platform technology that enables oral delivery of biologicals and large molecule drugs, which are typically delivered via injections and or other non-oral pathways. However, oral drug delivery is the easiest method for self-administering medications, offers patients greater dosing flexibility, and has the highest patient acceptance and compliance rates as compared to all other routes of drug administration. The Company employs this technology for its own pipeline products and may enter into licensing agreements with biopharma companies for application of the technology to their proprietary compounds, such as the Amgen strategic research collaboration. For more information on Entera Bio, visit www.enterabio.com. Forward Looking Statements This press release contains \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"may,\" \"should,\" \"...